2024 - 2032 年非动物替代测试市场机会、成长动力、产业趋势分析与预测

全球非动物替代测试市场在 2023 年价值 18 亿美元，预计 2024 年至 2032 年复合年增长率为 11.9%。围绕动物测试的道德担忧加剧，加上美国食品和药物管理局和欧盟等机构的监管倡议，加速了向人道测试替代方案的转变。这些政策促进对创新技术的投资，提供可行的、合乎道德的测试解决方案。近年来，技术进步使研究人员能够比传统的动物测试方法更准确地模拟人类生理反应。

这些创新改变了药物开发和安全测试，为人类生物学提供了预测性见解。此市场按产品类型分类，包括器官晶片、细胞系和组织模型。细胞系在 2023 年成为主导细分市场，市场价值达 12 亿美元。这些模型由于其模仿各种人体生理功能的适应性，在药效和毒性测试等领域变得非常有价值。

它们的大批量生产能力也使其成为高通量筛选过程的首选，确保获得监管和科学验证所必需的一致、可重复的结果。依技术划分，非动物替代测试市场分为细胞培养技术、高通量技术、分子成像和组学。细胞培养技术在 2023 年引领市场，占据 49.4% 的份额，因为它能够在体外培养和操纵人体细胞，为研究疾病和药物反应提供更相关的生物模型。该技术不仅提高了测试结果的可靠性，还支持细胞​​系的可扩展生产，简化了对药物发现至关重要的大量化合物的测试。

由于公众意识较高以及对动物测试的道德担忧日益增加，美国非动物替代测试市场预计到 2032 年将达到 19 亿美元。 2023年，美国在北美地区收入比重最大，总计6.566亿美元。公众对人道研究实践的需求促使製药公司在雄厚的资金和研究补助金（包括美国国立卫生研究院 (NIH) 的捐款）的支持下采用非动物测试。这些资金的涌入正在推动跨部门非动物测试方法的研究和应用，支持从动物模型的可持续过渡。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 药物开发的技术进步
    • 不断增加用于开发替代技术的投资和研究补助金
    • 越来越多地禁止使用动物模型进行研究
  • 产业陷阱与挑战
    • 与安全性、有效性和品质相关的严格法规
• 成长潜力分析
• 监管环境
  • 我们
  • 欧洲
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者细胞株竞争分析
• 主要市场参与者卫生纸生产线的竞争分析
• 器官晶片主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板
• 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032

• 主要趋势
• 器官晶片
• 细胞系
• 组织线

第 6 章：市场估计与预测：依方法，2021 - 2032

• 主要趋势
• 离体测试
• 电脑建模
• 细胞测定
• 生化检测

第 7 章：市场估计与预测：按技术分类，2021 - 2032

• 主要趋势
• 细胞培养技术
• 高通量技术
• 分子影像技术
• 组学技术

第 8 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 传染病
• 免疫疾病
• 肿瘤学
• 心血管疾病
• 糖尿病
• 遗传疾病
• 神经系统疾病

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 製药公司
• 生技公司
• 研究机构与学者
• 合约研究组织
• 其他最终用途

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯

第 11 章：公司简介

• AlveoliX
• BICO GROUP
• CN Bio Innovations
• Emulate
• Hesperos
• InSphero
• Lonza Group
• Merck
• MIMETAS
• Thermo Fisher Scientific
• TissUse
• VITROCELL Systems

The Global Non-Animal Alternative Testing Market, valued at USD 1.8 billion in 2023, is projected to expand at a CAGR of 11.9% from 2024 to 2032. This growth is driven by rising investments and research grants advancing alternative testing methods. Heightened ethical concerns surrounding animal testing, alongside regulatory initiatives from agencies such as the U.S. FDA and European Union, have accelerated the shift toward humane testing alternatives. These policies foster investment in innovative technologies that offer viable, ethical testing solutions. In recent years, technological advancements have allowed researchers to simulate human physiological responses with more accuracy than traditional animal testing methods.

These innovations transform drug development and safety testing, providing predictive insights into human biology. The market, categorized by product type, includes organ-on-chips, cell lines, and tissue models. Cell lines emerged as the leading segment in 2023, capturing a market value of USD 1.2 billion. These models have become invaluable in fields like drug efficacy and toxicity testing due to their adaptability in mimicking various human physiological functions.

Their capability for high-volume production also makes them a preferred choice for high throughput screening processes, ensuring consistent, reproducible results essential for regulatory and scientific validation. By technology, the non-animal alternative testing market segments into cell culture technology, high-throughput technology, molecular imaging, and omics. Cell culture technology led the market in 2023, with a 49.4% share, due to its capacity to grow and manipulate human cells in vitro, offering a more relevant biological model for studying diseases and drug responses. This technology not only enhances the reliability of test outcomes but also supports the scalable production of cell lines, streamlining the testing of vast numbers of compounds essential for drug discovery.

U.S. non-animal alternative testing market is expected to reach USD 1.9 billion by 2032, led by high public awareness and mounting ethical concerns over animal testing. In 2023, the U.S. accounted for the largest revenue share in North America, totaling USD 656.6 million. Public demand for humane research practices has prompted pharmaceutical companies to adopt non-animal testing, backed by robust funding and research grants, including contributions from the National Institutes of Health (NIH). This influx of funding is fueling both research and application of non-animal testing methods across sectors, supporting a sustainable transition away from animal-based models.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Technological advances in drug development
    • 3.2.1.2 Growing investments and research grants for developing alternative technologies
    • 3.2.1.3 Increasing ban on using animal models for research purposes
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulations related to safety, efficacy and quality
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players cell line
• 4.4 Competitive analysis of major market players tissue line
• 4.5 Competitive analysis of major market players organ-on-chips
• 4.6 Competitive positioning matrix
• 4.7 Strategy dashboard
• 4.8 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Organ-on-chips
• 5.3 Cell lines
• 5.4 Tissue lines

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Ex vivo testing
• 6.3 Computer modelling
• 6.4 Cellular assay
• 6.5 Biochemical assay

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cell culture technology
• 7.3 High throughput technology
• 7.4 Molecular imaging technology
• 7.5 Omics technology

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Infectious diseases
• 8.3 Immunological diseases
• 8.4 Oncology
• 8.5 Cardiovascular diseases
• 8.6 Diabetes
• 8.7 Genetic diseases
• 8.8 Neurological diseases

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical companies
• 9.3 Biotechnological companies
• 9.4 Research institutes and academics
• 9.5 CROs
• 9.6 Other End Use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia

Chapter 11 Company Profiles

• 11.1 AlveoliX
• 11.2 BICO GROUP
• 11.3 CN Bio Innovations
• 11.4 Emulate
• 11.5 Hesperos
• 11.6 InSphero
• 11.7 Lonza Group
• 11.8 Merck
• 11.9 MIMETAS
• 11.10 Thermo Fisher Scientific
• 11.11 TissUse
• 11.12 VITROCELL Systems